Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today
announces an exclusive licensing and commercialisation agreement with Rakuten Medical, Inc.
(Rakuten Medical), a global biotechnology company developing and commercialising
precision, cell targeting therapies based on its proprietary Alluminox™ platform.
Under the terms of the agreement, Hikma has an exclusive license to commercialise products in
Rakuten Medical’s pipeline using its photoimmunotherapy technology platform, Alluminox™,
in all its MENA markets.
Commenting on the agreement, Mazen Darwazah, Hikma’s Executive Vice Chairman and
President of MENA, said: “This agreement allows us to work with an excellent global partner
to strengthen our growing portfolio in oncology and biotechnology. Most importantly, this
allows us to bring a potentially transformative technology to cancer patients in MENA, helping
to put better health within reach, everyday.”
Mickey Mikitani, Co-CEO of Rakuten Medical, added: “We are already developing
Alluminox™ treatment in several countries and regions, including the United States, Japan,
Taiwan, and India, and this agreement further accelerates our global expansion. With Hikma's
strong regional footprint and medical expertise, we expect the Alluminox™ platform to make
significant progress in MENA.”
